Recombinant human PH20 hyaluronidase (rHuPH20) is used to facilitate dispersion of subcutaneously delivered fluids and drugs. This report summarizes rHuPH20 immunogenicity findings from clinical trials where rHuPH20 was co-administered with SC human immunoglobulin, trastuzumab, rituximab, or insulin. Plasma samples were obtained from evaluable subjects… (More)
Errors by the authors were inadvertently published in Table I and the supplemental material. The correct Table I is below and the corrected supplemental material can be found by accessing the original article.